Overview
NVAX market data
Price History
NVAX price chart
Valuation & Profitability
- P/E (TTM)
- 2.98 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $2.54 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.52 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -59.9% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $6.20 – $11.97 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $1.3B · P/B 11.32 · P/S 3.17.
Company News
Trump Says Administration Recognizing Childhood Vaccine Recommendations For Only 11 Core Vaccinations; Hepatitis B, COVID-19, Influenza No Longer Recommended For All ChildrenBenzinga · Aug 10, 2026, 7:00 PM
8-K filing — NOVAVAX INC (NVAX)SEC EDGAR · Aug 6, 2026, 12:03 PM
Novavax Raises FY2026 Sales Guidance from $230.000M-$270.000M to $235.000M-$275.000M vs $389.234M EstBenzinga · Aug 6, 2026, 12:02 PM
Novavax Q2 EPS $(0.32) Beats $(0.37) Estimate, Sales $56.698M Beat $52.513M EstimateBenzinga · Aug 6, 2026, 11:52 AM
U.S. FDA Advisers Vote In Favor Of Recommending Covid Vaccines Target JN.1 Lineage XFG Variant For 2026-27 CampaignBenzinga · May 28, 2026, 6:29 PM